Alkermes to Take Part in the Stifel Virtual Healthcare Conference
Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the Stifel Virtual Healthcare Conference on November 16, 2021, at 9:20 a.m. ET. Investors can access the presentation via the Investors tab on the company's website. Alkermes focuses on developing innovative medicines in neuroscience and oncology, with a range of products targeting addiction, schizophrenia, and bipolar I disorder. The company has R&D facilities in Massachusetts and manufacturing sites in Ireland and Ohio.
- Participation in the Stifel Virtual Healthcare Conference could enhance investor engagement.
- Alkermes has a diverse portfolio of proprietary commercial products and a strong pipeline in neurodegenerative disorders and cancer.
- None.
Insights
Analyzing...
DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel Virtual Healthcare Conference on Tuesday, Nov. 16, 2021 at 9:20 a.m. ET (2:20 p.m. GMT). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Contact:
Alex Braun
Investor Relations
+1 781 296 8493
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-stifel-virtual-healthcare-conference-301420297.html
SOURCE Alkermes plc